We break down the triple-agonist research everyone is arguing about, what the published data actually shows, and where the hype outruns the science.
Long-form conversations with researchers, formulators, and the people actually moving this industry. No fluff, no sales pitch.
What changed this week, why it matters, and what the headlines leave out.
Straight from the group chats, comment sections, and forums.
New episodes, the research worth reading, and what the community is talking about. One email a week. No spam.
Join 120,000+ readers. Unsubscribe anytime.